A Phase I, Open-label, Multicenter, Dose Escalation and Expansion Study to Evaluate the Tolerance and Pharmacokinetics of TQB3474 Injection
Latest Information Update: 07 Oct 2021
At a glance
- Drugs TQB 3474 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 06 Nov 2019 New trial record